NextCure announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease, or COPD, at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy. VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades. Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins. This immunosuppressive function, combined with the strong expression profile of VSTM-1 on pulmonary myeloid cells and the prominent role of neutrophils as inflammatory mediators of lung immunopathology, makes VSTM-1 a promising novel therapeutic target for COPD. NextCure developed an agonist monoclonal antibody, or mAb, against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease. The agonist antibody has demonstrated activity in vitro, ex vivo and in highly relevant in vivo models. Key findings from the study include: The agonist antibody blocks neutrophil-mediated inflammation and cytokine production associated with tissue damage in vitro and ex vivo. Treatment with the agonist antibody reduces pulmonary pathology and prevents disease in animal models, including a highly relevant syngeneic mouse model engineered to express the human VSTM-1 protein. Additional preclinical chronic models of inflammatory disease and relevant, mechanistically based combination studies in COPD and other indications are being planned.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NXTC:
- NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
- NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
- NextCure announces publication of non-clinical data on Anti-Siglec-15 treatment
- NextCure Provides Year-End Clinical Pipeline Updates
- NextCure provides year-end clinical pipeline updates